PARP inhibitors olaparib and talazoparib as treatment for metastatic breast cancer

Bookmark and Share
Published: 18 Jun 2019
Views: 721
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Dr Matteo Lambertini talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about two PARP inhibitor agents that are approved for treatment in metastatic breast cancer.

He explains that they have been studied in two similar randomised trials showing similarly promising results.

Dr Lambertini explains that going forward it is key to understand whether these agents can be used in the early setting but that trials are underway researching this.

This programme has been supported by an unrestricted educational grant from Pfizer.